Study wants to explore real-world data in three distinct settings
* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN
Patients aged >18y
Cytological or Histologically confirmed diagnosis of PC
Histologically or radiologically confirmed diagnosis of metastatic disease and
HRD POSITIVE STATUS
Patients without histologically confirmed diagnosis of PC
Patients without histologically or radiologically confirmed metastatic disease and
HRD NEGATIVE STATUS
Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study